2.

Univariate and multivariate analysis of prognostic factors associated with OS and DFS in 74 patients with HCC.

Variables	Number	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
		3-year OS (%)	P		HR (95% CI)	P		3-year DFS (%)	P		HR (95% CI)	P
Data are presented as HR (95% CI) and P-value. †I, cPLA2αLow/p-FAKLow; II, cPLA2αLow/p-FAKHigh and cPLA2αHigh/p-FAKLow; III, cPLA2αHigh/p-FAKHigh. *P < 0.05 was considered statistically significant. Abbreviations: OS, overall survival; DFS, disease free survival; AFP, alpha fetoprotein; ALB, albumin; HBV, hepatitis B virus; HCV, hepatitis C virus; MVI, microvascular invasion; MAVI, macrovascular invasion; N/Y, no/yes; L/H, low/high.
Age (years) (≤ 55/> 55)	43/31	65.1/58.1	0.665					51.2/35.5	0.290
Gender (male/female)	60/14	60.0/71.4	0.503					46.7/35.7	0.369
AFP (μg/L) (≤ 400/> 400)	47/27	66.0/55.6	0.343					48.9/37.0	0.249
ALB (g/L) (≤ 40/> 40)	25/49	64.0/61.2	0.926					44.0/44.9	0.808
Tumor size (cm) (≤ 5/> 5)	35/39	71.4/53.8	0.116					57.1/33.3	0.055
Tumor number (≤ 1/> 1)	58/16	67.2/43.8	0.088					46.6/37.5	0.428
HBV (N/Y)	21/53	57.1/64.2	0.643					42.9/45.3	0.869
HCV (N/Y)	68/6	66.2/16.7	0.009*		1.81 (0.65, 5.02)	0.256		47.1/16.7	0.123
Liver cirrhosis (N/Y)	38/36	55.3/69.4	0.310					34.2/55.6	0.112
Tumor encapsulation (N/Y)	70/4	60.0/0	0.155					41.4/0	0.062
Tumor thrombus (N/Y)	26/48	61.5/62.5	0.793					50.0/41.7	0.626
Satellite nodule (N/Y)	48/26	66.7/53.8	0.179					45.8/42.3	0.670
MVI (N/Y)	70/4	62.9/50.0	0.491					44.3/50.0	0.820
MAVI (N/Y)	68/6	66.2/16.7	0.000*		1.93 (0.67, 5.61)	0.226		48.5/0	0.000*		1.79 (0.68, 4.71)	0.239
p-FAK (L/H)	40/34	82.5/38.2	0.000*		3.34 (1.37, 8.18)	0.008*		65.0/20.6	0.000*		2.28 (1.18, 4.38)	0.014*
cPLA2α (L/H)	50/24	78.0/29.2	0.000*		4.20 (1.68, 10.46)	0.002*		60.0/12.5	0.000*		3.97 (1.97, 8.01)	0.000*
p-FAK + cPLA2α†			0.000*		1.59 (0.66, 3.83)	0.303			0.000*		2.05 (1.07, 3.93)	0.031*
I	31	90.3						77.4
II	28	57.1						28.6
III	15	13.3						6.7